Back
Also listed as
GLAXF
OTC
Day Range
$51.80
$52.69
52-Week Range
$32.38
$61.70
Volume
4,212,688
50D / 200D Avg
$54.58
/
$45.66
Prev Close
$51.84
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 18.7 | 0.4 |
| P/B | 6.4 | 2.9 |
| ROE % | 37.3 | 3.8 |
| Net Margin % | 17.5 | 3.9 |
| Rev Growth 5Y % | 6.7 | 10.0 |
| D/E | 1.1 | 0.2 |
Insider Trading Activity
Buy ratio (90d)
0.0%
10 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 3, 2026 |
Braunstein Scott
|
sell | 29,956 | — | — |
| Mar 3, 2026 |
Dombkowski Ashley L.
|
sell | 29,956 | — | — |
| Mar 3, 2026 |
Lyons-Williams Lori
|
sell | 47,240 | — | — |
| Mar 3, 2026 |
Giordano Michael F
|
sell | 48,328 | — | — |
| Mar 3, 2026 |
Young Rodney KB
CHIEF FINANCIAL OFFICER
|
sell | 205,703 | — | — |
| Mar 3, 2026 |
Kozick Linda
|
sell | 51,762 | — | — |
| Mar 3, 2026 |
Brockstedt Dirk G.
CHIEF SCIENTIFIC OFFICER
|
sell | 164,742 | — | — |
| Mar 3, 2026 |
GRAY MARY ANN
|
sell | 59,858 | — | — |
| Mar 3, 2026 |
Wong Brian Russell
PRESIDENT AND CEO
|
sell | 827,353 | — | — |
| Dec 11, 2025 |
GSK plc
10% Owner
|
buy | 1,470,000 | $19.00 | $27,930,000 |
Key Takeaways
Revenue grew 6.65% annually over 5 years — modest growth
Earnings grew 117.12% over the past year
ROE of 37.25% indicates high profitability
Net margin of 17.50% shows strong profitability
Generating 5.82B in free cash flow
PEG of 0.11 suggests growth is underpriced
Growth
Revenue Growth (5Y)
6.65%
Revenue (1Y)1.83%
Earnings (1Y)117.12%
FCF Growth (3Y)-3.52%
Quality
Return on Equity
37.25%
ROIC15.45%
Net Margin17.50%
Op. Margin21.95%
Safety
Debt / Equity
1.08
Current Ratio0.82
Interest Coverage10.23
Valuation
P/E Ratio
18.68
P/B Ratio6.39
EV/EBITDA16.93
Dividend Yield0.03%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 1.83% | Revenue Growth (3Y) | 2.64% |
| Earnings Growth (1Y) | 117.12% | Earnings Growth (3Y) | 6.51% |
| Revenue Growth (5Y) | 6.65% | Earnings Growth (5Y) | 6.26% |
| Profitability | |||
| Revenue (TTM) | 31.95B | Net Income (TTM) | 5.59B |
| ROE | 37.25% | ROA | 9.16% |
| Gross Margin | 72.54% | Operating Margin | 21.95% |
| Net Margin | 17.50% | Free Cash Flow (TTM) | 5.82B |
| ROIC | 15.45% | FCF Growth (3Y) | -3.52% |
| Safety | |||
| Debt / Equity | 1.08 | Current Ratio | 0.82 |
| Interest Coverage | 10.23 | Dividend Yield | 0.03% |
| Valuation | |||
| P/E Ratio | 18.68 | P/B Ratio | 6.39 |
| P/S Ratio | 3.27 | PEG Ratio | 0.11 |
| EV/EBITDA | 16.93 | Dividend Yield | 0.03% |
| Market Cap | 104.42B | Enterprise Value | 118.72B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 31.95B | 31.38B | 30.33B | 29.32B | 24.70B |
| Net Income | 5.59B | 2.58B | 4.93B | 14.96B | 4.39B |
| EPS (Diluted) | 2.72 | 1.24 | 2.40 | 2.40 | 2.70 |
| Gross Profit | 23.18B | 22.33B | 21.76B | 19.77B | 16.53B |
| Operating Income | 7.01B | 4.02B | 6.75B | 6.43B | 4.36B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 61.01B | 59.46B | 75.22B | 60.15B | 107.14B |
| Total Liabilities | 45.02B | 46.38B | 58.91B | 50.05B | 78.23B |
| Shareholders' Equity | 16.35B | 13.67B | 17.01B | 10.60B | 20.39B |
| Total Debt | 17.69B | 16.99B | 22.97B | 20.99B | 32.74B |
| Cash & Equivalents | 3.39B | 3.69B | 3.74B | 3.72B | 5.79B |
| Current Assets | 17.48B | 17.00B | 23.77B | 20.77B | 25.29B |
| Current Liabilities | 21.35B | 21.70B | 26.86B | 22.81B | 32.06B |